Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
MORRISVILLE, N.C., Oct. 27, 2017 -- Hampton Corley, Chief Business Officer of Clinipace Worldwide, a global full-service clinical research organization (CRO), has been appointed to the Board of Directors of the American Society of Nephrology’s Kidney Health Initiative (KHI). Corley will serve on the Board for a renewable three-year term from January 1, 2018, to December 31, 2020.
“I welcome this opportunity to support the efforts of the KHI,” said Corley. “Our company endorses the initiative’s mission of advancing scientific understanding of the kidney health and patient safety implications of new and existing medical products, and therapy development of therapies for kidney disease – an area of great unmet need.”
“Nephrology is a key therapeutic area for Clinipace going forward,” said Eric B. Grossman, MD, Vice President and Medical Director of Clinipace Worldwide. “We especially support the KHI’s efforts to create a collaborative environment in which sponsors, regulators, Principal Investigators and the greater nephrology community can interact to optimize evaluation of therapies.”
Clinipace will attend the KHI Open House on Friday, November 3, in New Orleans, during the ASN Kidney Week.
About Clinipace Worldwide
Clinipace Worldwide, a global full-service clinical research organization (CRO) serves the unique needs of venture-backed, mid-tier and strategic pharmaceutical, biotechnology and medical device firms, helping them advance drug candidates to deliver successful stakeholder and patient outcomes. The company leverages extensive therapeutic knowledge and clinical trial expertise to support life science firms in achieving some of their most important goals: executing regulatory strategies, optimizing clinical development timelines and completing high quality trials. Committed to delivering against timelines and milestone events, Clinipace has completed more than 1,500 clinical trials and 1,500 regulatory and statistical consulting projects and operates in North America, South America, Europe, and Asia. To learn more, visit www.clinipace.com.
Media Contact:
Sandra Parrish Woodlief
919-797-9480
